

CHANGE OF MANAGEMENT AT NOXXON

Berlin, 10. May 2006 – NOXXON Pharma AG announced today that Thomas Klein resigned from his position as Chief Executive of NOXXON with immediate effect. The decision is the consequence of a realignment of NOXXON's corporate strategy and was made in mutual agreement between the supervisory board and Mr Klein. The board and all NOXXON employees thanked Mr Klein for his outstanding service and leadership to the company.

Dr. Sven Klussmann, founder and CSO of NOXXON, will assume all management responsibilities. NOXXON's supervisory board, headed by Dr. Max Link, has begun to interview candidates to strengthen the Executive Board.

About NOXXON Pharma AG, the next generation aptamer company:

Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website: <http://www.noxxon.net>

Kontakt: Esther Brimacombe
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49 30 72 62 47 0
FAX: + 49 30 72 62 47 225
Email: ebrimacombe@noxxon.net